https://orcid.org/0000-0001-7946-7145
References
- Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol. 2008;180(2):444–450.
- Tabib C, Nethala D, Kozel Z, et al. Management and treatment options when facing malignant ureteral obstruction. Int J Urol. 2020;27(7):591–598. Available from: 10.1111/iju.14235
- Wong LM, Cleeve LK, Milner AD, et al. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol. 2007;178:178–183.
- Haifler M, Shvero A, Zilberman D, et al. Tandem ureteral stents for malignant ureteral obstruction. J Endourol. 2020;34(2):222–226.
- Savin Z, Herzberg H, Ben-David R, et al. Long-term follow-up of yearly replaced double internal stents for extrinsic malignant ureteral obstruction. J Endourol. 2021;35(1):71–76.
- Haifler M, Kleinmann N, Weiss D. Tandem ureteral stents drainage lowers renal pelvis pressure in malignant ureteral obstruction: experimental and computational models. J Biomech. 2021;117:110237.
- Elsamra SE, Leavitt DA, Motato HA, et al. Stenting for malignant ureteral obstruction: tandem, metal or metal‐mesh stents. Int J Urol. 2015;22(7):629–636.
- Monsky WL, Molloy C, Jin B, et al. Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc Intervent Radiol. 2013;36(5):1355–1363.
- Ishioka J, Kageyama Y, Inoue M, et al. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J. Urol. 2008;180(2):618–621.
- Lienert A, Ing A, Mark S. Prognostic factors in malignant ureteric obstruction. BJU Int. 2009;104(7):938–941.
- Cordeiro MD, Coelho RF, Chade DC, et al. A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU Int. 2016;117(2):266–271.
- Azam F, Latif MF, Farooq A, et al. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019;12(3):728–736.
- Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
- Abu-Shawer O, Abu-Shawer M, Hirmas N, et al. Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer. 2019;19(1):141.
- Rossi S, Basso M, Strippoli A, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer? Clin Colorectal Cancer. 2017;16(4):264–274.
- Hirahara T, Arigami T, Yanagita S, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672.
- Izumi K, Mizokami A, Maeda Y, et al. Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction. J Urol. 2011;185(2):556–561.
- Bilen MA, Shabto JM, Martini DJ, et al. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer. 2019;19(1):857.
- Wang J, Li S, Liu Y, et al. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis. Cancer Med. 2020;9(1):361–373.
- Dong F, Shen Y, Gao F, et al. Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study. Cancer Manag Res. 2017;9:611–626.